PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22407500-4 2012 By disrupting VMAT2 function, reserpine depleted DA stores, and increased glutamate and hydroxyl radical levels in the rat striatum. Reserpine 30-39 solute carrier family 18 member A2 Rattus norvegicus 14-19 19429089-5 2009 Moreover, kinetic analysis revealed that inhibition by reserpine, a typical VMAT2 inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine. Reserpine 55-64 solute carrier family 18 member A2 Rattus norvegicus 76-81 17425337-6 2007 However, a significant increase in the cell death was observed when DT-diaphorase was inhibited when the cells were incubated with 1 microM reserpine and 100 microM dopamine for 12 h since at this concentration reserpine inhibits VMAT-2 but not DT-diaphorase. Reserpine 140-149 solute carrier family 18 member A2 Rattus norvegicus 230-236 18579341-11 2008 Moreover, opposite effects were observed in PC12 cells pretreated with the specific VMAT(2) inhibitor reserpine. Reserpine 102-111 solute carrier family 18 member A2 Rattus norvegicus 84-91 17244889-7 2007 In addition, dopamine secretion was prevented by the VMAT-1/VMAT-2 inhibitor reserpine but not by the VMAT-2 inhibitor tetrabenazine. Reserpine 77-86 solute carrier family 18 member A2 Rattus norvegicus 60-66 17425337-6 2007 However, a significant increase in the cell death was observed when DT-diaphorase was inhibited when the cells were incubated with 1 microM reserpine and 100 microM dopamine for 12 h since at this concentration reserpine inhibits VMAT-2 but not DT-diaphorase. Reserpine 211-220 solute carrier family 18 member A2 Rattus norvegicus 230-236 9931359-3 1999 The cells are rich in the vesicle monoamine transporter type-2 (VMAT-2), which can be inhibited by reserpine. Reserpine 99-108 solute carrier family 18 member A2 Rattus norvegicus 26-62 16835371-2 2006 Some compounds, such as reserpine, "release" neurotransmitter by inhibiting the ability of VMAT(2) to accumulate neurotransmitter in the vesicle, whereas other types of compounds can release neurotransmitter via a carrier-mediated exchange mechanism. Reserpine 24-33 solute carrier family 18 member A2 Rattus norvegicus 91-98 15544835-2 2005 The objective of this study was to investigate the generation of WE-14 in the endocrine cell types of the oxyntic mucosa of the stomach, after treatment with reserpine, an irreversible inhibitor of vesicular monoamine uptake 2 (VMAT2). Reserpine 158-167 solute carrier family 18 member A2 Rattus norvegicus 228-233 10332097-9 1999 This inhibition was stereospecific and sensitive to reserpine (50 nM), which blocks VMAT1 and VMAT2, but resistant to tetrabenazine, which is a selective inhibitor of VMAT2. Reserpine 52-61 solute carrier family 18 member A2 Rattus norvegicus 94-99 9931359-3 1999 The cells are rich in the vesicle monoamine transporter type-2 (VMAT-2), which can be inhibited by reserpine. Reserpine 99-108 solute carrier family 18 member A2 Rattus norvegicus 64-70 25445479-1 2015 Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2) and monoamine releaser, so it can be used as a pharmacological model of depression. Reserpine 0-9 solute carrier family 18 member A2 Rattus norvegicus 33-66 9131778-1 1997 The vesicular monoamine transporter-2 (VMAT2) mediates the reserpine-sensitive neuronal uptake of monoamines into vesicles and other intracellular organelles. Reserpine 59-68 solute carrier family 18 member A2 Rattus norvegicus 4-37 9131778-1 1997 The vesicular monoamine transporter-2 (VMAT2) mediates the reserpine-sensitive neuronal uptake of monoamines into vesicles and other intracellular organelles. Reserpine 59-68 solute carrier family 18 member A2 Rattus norvegicus 39-44 34727322-3 2021 Reserpine functions by inhibiting vesicular monoamine transporter 2 (VMAT2), reducing sequestration of monoamines into synaptic vesicles. Reserpine 0-9 solute carrier family 18 member A2 Rattus norvegicus 34-67 34727322-3 2021 Reserpine functions by inhibiting vesicular monoamine transporter 2 (VMAT2), reducing sequestration of monoamines into synaptic vesicles. Reserpine 0-9 solute carrier family 18 member A2 Rattus norvegicus 69-74 3792636-1 1987 The binding of [3H]dihydrotetrabenazine ([3H]TBZOH), a specific ligand of the reserpine-sensitive monoamine transporter in brain and adrenal medulla storage vesicles, has been measured in cultured sympathetic neurons from newborn rat in relation to their neurotransmitter phenotype. Reserpine 78-87 solute carrier family 18 member A2 Rattus norvegicus 98-119 28396635-1 2017 Reserpine is an irreversible inhibitor of vesicular monoamine transporter-2 (VMAT2) used to study Parkinson"s disease (PD) and screening for antiparkinsonian treatments in rodents. Reserpine 0-9 solute carrier family 18 member A2 Rattus norvegicus 42-75 28396635-1 2017 Reserpine is an irreversible inhibitor of vesicular monoamine transporter-2 (VMAT2) used to study Parkinson"s disease (PD) and screening for antiparkinsonian treatments in rodents. Reserpine 0-9 solute carrier family 18 member A2 Rattus norvegicus 77-82 9192308-10 1997 The effect of L-DOPA was reversed by reserpine, which inhibits the amine-proton exchangers VMAT1 and VMAT2, and by carbidopa, which inhibits aromatic L-amino acid decarboxylase. Reserpine 37-46 solute carrier family 18 member A2 Rattus norvegicus 101-106 33971246-1 2021 Reserpine (RES) is an irreversible inhibitor of VMAT2 used to study Parkinson"s disease (PD) and screening for antiparkinsonian treatments in rodents. Reserpine 0-9 solute carrier family 18 member A2 Rattus norvegicus 48-53 33971246-1 2021 Reserpine (RES) is an irreversible inhibitor of VMAT2 used to study Parkinson"s disease (PD) and screening for antiparkinsonian treatments in rodents. Reserpine 11-14 solute carrier family 18 member A2 Rattus norvegicus 48-53 25445479-1 2015 Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2) and monoamine releaser, so it can be used as a pharmacological model of depression. Reserpine 0-9 solute carrier family 18 member A2 Rattus norvegicus 68-73 25445479-12 2015 On the basis of the presented behavioral and neurochemical experiments, we suggest that chronic administration of reserpine even in such low dose which not yet acted on the release of monoamines but produced an inhibition of VMAT2 caused a long-lasting disadvantageous effect of plasticity in the brain resembling depressive disorders. Reserpine 114-123 solute carrier family 18 member A2 Rattus norvegicus 225-230 23875622-8 2013 These results support a hypothetical model of GZ-793A interaction at more than one site on the VMAT2 protein, which explains its potent inhibition of dopamine uptake, dopamine release via a High-affinity tetrabenazine- and reserpine-sensitive site, dopamine release via a Low-affinity tetrabenazine- and reserpine-insensitive site, and a low-affinity interaction with the dihydrotetrabenazine binding site on VMAT2. Reserpine 223-232 solute carrier family 18 member A2 Rattus norvegicus 95-100 23875622-8 2013 These results support a hypothetical model of GZ-793A interaction at more than one site on the VMAT2 protein, which explains its potent inhibition of dopamine uptake, dopamine release via a High-affinity tetrabenazine- and reserpine-sensitive site, dopamine release via a Low-affinity tetrabenazine- and reserpine-insensitive site, and a low-affinity interaction with the dihydrotetrabenazine binding site on VMAT2. Reserpine 304-313 solute carrier family 18 member A2 Rattus norvegicus 95-100